GRAIL to Supply Multi-Cancer Early Detection Blood Test to UK

Menlo Park, Calif.-based GRAIL announced a partnership with the UK’s National Health Service (NHS) that will make the company’s multi-cancer early detection blood test, Galleri, available to NHS patients starting in 2021.

The partnership program aims to confirm the product’s performance ahead of its routine use by the NHS. The initial program will involve approximately 165,000 patients.

Based on data from the program, access to the test could be expanded to around 1 million people by 2025 and potentially to a larger population going forward, the company said.

Galleri is also expected to be commercially available in the U.S. in 2021.